Toxic protein linked to muscular dystrophy and arhinia

Researchers at the National Institutes of Health and their colleagues have found that a toxic protein made by the body called DUX4 may be the cause of two very different rare genetic disorders.

Toxic protein linked to muscular dystrophy and arhinia. Photo: National Cancer Institute/Unsplash

For patients who have facioscapulohumeral muscular dystrophy (FSHD), or a rare facial malformation called arhinia, this research discovery may eventually lead to therapies that can help people with these rare diseases.

FSHD type 2 (FSHD2) is an inherited form of muscular dystrophy that causes progressive muscle weakness.

Arhinia is an extremely rare yet severe disorder that prevents the development of an external nose and the olfactory bulbs and tracts. Both diseases are caused by mutations in the SMCHD1 gene.

In patients with FSHD2, there is overproduction of DUX4 which kills the muscle cells, and this leads to the progressive weakening of the muscles.

“It has been known for some time that DUX4 damages the muscle in patients with FSHD2, but what we found is that it can actually also kill the precursors of the human nose,” said Natalie Shaw, M.D., head of the Pediatric Neuroendocrinology Group at the National Institute of Environmental Health Sciences (NIEHS) and lead author of the new study.

Shaw’s team found that the combination of the mutated SMCHD1 gene and an environmental modifier such as a virus, may trigger the DUX4 toxic protein. This may be what causes arhinia to occur.

Using stem cells created from patients with the two diseases, the researchers conducted studies in cranial placode cells, the cells that lead to the development of the body’s sensory organs, such as the nose.

As the placode cells started to form, they began to produce the DUX4 protein which caused cell death.

The researchers showed that DUX4 is responsible for cell death in placode cells as it is in muscle cells, but they still do not understand why the nose cells do not die in muscular dystrophy or why the muscle cells are not dying in arhinia.

“Now what we have to do is try to figure out the players acting downstream of DUX4, so we can block it from damaging the muscle cells or the nose precursors and hopefully find some new treatment options for patients suffering from these rare diseases,” said Shaw. (National Institutes of Health)

YOU MAY ALSO LIKE

Computational study finds genetic links, therapy targets for varicose veins

Scientists at the Department of Energy’s Oak Ridge National Laboratory explored the genetic basis of varicose veins. The team identified 139 locations across the human genome tied to risk factors for the disorder that can guide the development of new treatments.

Researchers identify compounds that could lead to an on-demand, short-term contraceptive for men

In a mouse study, researchers have identified a potential non-hormonal contraceptive that men could take shortly before sexual activity and have fertility restored the next day.

Studies find that microbiome changes may be a signature for ME/CFS

Researchers have found differences in the gut microbiomes of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) compared to healthy controls.

Artificial pancreas successfully trialled for use by type 2 diabetes patients

Cambridge scientists have successfully trialled an artificial pancreas for use by patients living with type 2 diabetes.

New MRI method provides detailed view of the placenta during pregnancy

New technique enables automatic detection of placental compartments, oxygen status and structural abnormalities.

Cellular 'glue' to regenerate tissues, heal wounds, regrow nerves

Synthetic molecules that adhere cells could galvanize regenerative medicine.